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E-08010 Barcelona, SpainABSTRACT Computer simulations have been demonstrated to be important for unraveling atomic mechanisms in biological
systems. In this study, we show how combining unbiased molecular dynamic simulations with appropriate analysis tools can
successfully describe metal-based drug interactions with DNA. To elucidate the noncovalent affinity of cisplatin’s family to
DNA, we performed extensive all-atom molecular dynamics simulations (3.7 ms total simulation length). The results show
that the parent drug, cisplatin, has less affinity to form noncovalent adducts in the major groove than its aquo complexes.
Furthermore, the relative position in which the drugs enter the major groove is dependent on the compound’s net charge. Based
on the simulations, we estimated noncovalent binding free energies through the use of Markov state models. In addition, and to
overcome the lack of experimental information, we employed two additional methods: Molecular Mechanics Poisson-Boltzmann
Surface Area (MMPB-SA) and steered molecular dynamics with the Jarzynski estimator, with an overall good agreement
between the three methods. All complexes show interaction energies below 3 kcal/mol with DNA but the charged hydrolysis
products have slightly more favorable binding free energies than the parent drug. Moreover, this study sets the precedent for
future unbiased DNA-ligand simulations of more complex binders.INTRODUCTIONIndependently of the system of interest, an atomic-level un-
derstanding of how drugs find the binding site of their targets
is crucial. To this aim, specialized software and hardware,
together with state-of-the-art analysis algorithms, make in
silico techniques important tools when studying a new
drug. Biased molecular dynamics simulations have long
been used to compute binding free energies (1–4). More
recently, breakthrough computational studies have described
the unbiased protein-ligand molecular association (5–8).
Nevertheless, a nondriven all-atom association mechanism
between ligands (in particular metal-based) and DNA, an
important chemotherapeutic target, has not been addressed.
In the present work we report, for the first time to our knowl-
edge, how cisplatin findsDNAprevious to chemical reaction.
We analyzed microsecond-long unbiased molecular dy-
namics simulations and used Markov state models (MSMs)
to elucidate the kinetics and thermodynamics of the electro-
static preassociation between cisplatin and DNA. A better
understanding of these complex mechanisms, at atomic
level, is essential to improve platinum-based therapy.
The drug, clinically known as cisplatin (9,10) (cis-diammi-
nedichloro platinum(II)) and its derivates, are among the
most widely used antineoplastic agents (11,12). In addition
to testicular treatment (with more than 95% success rate
(13)), these platinum (Pt) compounds have worldwide appli-
cation inmany types of humanmalignancies (14,15). Regard-
less of the high efficacy of cisplatin, it has many side effectsSubmitted May 30, 2013, and accepted for publication November 22, 2013.
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0006-3495/14/01/0421/9 $2.00and is innate along with acquired resistance that reduces its
medical value. Although this drug was accidentally discov-
ered, newer generations have been designedwith characteris-
tics aimed to reduce its undesirable side effects and increase
its efficacy toward a larger spectrum of tumors. The curing
rates of cisplatin analogs, however, have not been signifi-
cantly improved aftermore than 40 years of research (16–18).
It is commonly accepted that the antineoplastic effects
produced by cisplatin and other platinum drugs result from
covalent attachment between the platinum atom and the elec-
tron-rich atoms in DNA bases (19–21). However, before this
binding event, a wealth of physiologic reactions occurs.
Upon intravenous administration, the high chloro (Cl) con-
centration, found in blood plasma, hinders the replacement
of the labile Cl ions. When the cell membrane is crossed,
however, through passive diffusion or by Cu-transporting
proteins (22,23), the Cl concentration drops from ~ 100 to
3 mM inducing hydrolysis reactions. Two species are
formed: the mono-aquo and the di-aquo complexes resulting
from one or two replacements of the Cl ligands by water
molecules, respectively (24,25). In addition to DNA, plat-
inum compounds can react with many biological targets.
For example, reaction with proteins, in particular those con-
taining thiol groups (26), have been proposed to be respon-
sible for the severe side effects accompanying platinum
drugs intake (27,28). The need for a complete understanding
of the different stages of these drugs’ action has prompted
innumerous studies at the computational level. There have
been studies on the hydrolysis reactions of these drugs using
high-level quantum methods (29–34), the interaction with
cysteine andmethioninemodels (35), or the covalent binding
to DNA (36–38). Also, the effect on DNA’s structure on thehttp://dx.doi.org/10.1016/j.bpj.2013.11.4494
422 Lucas et al.binding of platinum drugs has been explored (39–41). How-
ever, despite the wealth of computational work various
aspects remain unstudied, in many cases, because of the
complexity of the processes involved.
The negatively chargedDNAmolecule, and its high ability
for hydrogen bond (Hbond) formation, attracts cations and
Hbond donors to its surface. This leads to a very specific
microenvironment that will affect chemical reactions. In
the case of cisplatin, studies have shown that the binding rates
are improved because of weak interactions between the plat-
inum complex and DNA (42). The electrostatic preassocia-
tion is expected to affect the reaction rates and positions of
platination by increasing the local concentration of the
drug in particular sites (42–44). In this work, we study this
association before covalent binding and how the process
diverges from the parent drug, cisplatin, and its hydrolysis
products. Fig. 1 depicts the studied compounds: CPT for
cisplatin, CPT1 for the mono-aquo complex, and CPT2 for
the di-aquo complex.
We performed extensive molecular dynamic simulations
for these compounds and the results show unique character-
istics for each one. The parent drug exhibits extremely low
affinity for DNA thus confirming the unlikelihood of direct
binding. The higher affinity of the aquo complexes is
because of long-range electrostatic interactions that are
the main driving force for preassociation to the major
groove. Our results provide essential knowledge of the
initial noncovalent binding of these compounds, which is
valuable information in understanding the covalent addition
to DNA and therefore help in designing new compounds.
Finally, this work illustrates how microsecond-long sim-
ulations allow for an atomistic description of DNA-ligand
interactions. These simulations are now possible in a couple
of weeks of computing time (for example, in a small cluster
of graphic processing units) making them exceptionally
valuable for systematic application.MATERIAL AND METHODS
MD simulations
We have investigated the noncovalent binding of cisplatin to DNA using
unrestrained molecular dynamics (MD) simulation performed with the
PMEMD CUDA module within the AMBER11 molecular modeling suitFIGURE 1 Compounds investigated in this work (left to right): CPT—
parent drug (cisplatin with a net charge of 0); CPT1—mono-aquo complex
(formal chargeþ1); CPT2—di-aquo complex (formal chargeþ2). The cen-
tral atom in all compounds (dark blue) is a platinum (II) atom. To see this
figure in color, go online.
Biophysical Journal 106(2) 421–429(45). The parm99 force field with the parmbsc0 refinement was used for
DNA (46–48) whereas most parameters for the ligands have been derived
in this work through quantum mechanical calculations. Some parameters
were already available either in the literature or in the general AMBER
force field (GAFF) (49,50). Waters were incorporated as TIP3P model
(51). The ligands’ partial charges, were derived by fitting the electrostatic
potential obtained at HF/6-31G(d) level (calculated with Gaussian 03)
through the restrained electrostatic potential (RESP) method and are avail-
able in the Supporting Material (50,52). The initial DNA structure was
taken from the protein database (PDB) entry 2K0V (53) corresponding to
an undamaged sequence ((CCTCTGGTCTCC)$(GGAGACCAGAGG)).
This structure has been chosen because it has an identical sequence to an
available crystal structure of a DNA strand containing a cisplatin cross-
link (3LPV) (54).
We prepared all systems following the same procedure. The DNA þ
Pt-complexes were neutralized (because we wished to simulate the cell
environment with Cl- concentration of ~ 3 mM, no additional salt was
added) by addition of the convenient number of Naþ ions and then sur-
rounded by a 15 A˚ layer of preequilibrated water molecules in a truncated
octahedron box containing ~ 45,000 atoms. First, the system was mini-
mized through 10,000 steps: 5000 for ions and water minimization followed
by 5000 for the entire system. Then the system’s temperature was progres-
sively raised to 300 K using a weak-coupling algorithm during 200 ps of
constant pressure dynamics. A time step of 0.5 fs was used throughout
the simulations in combination with the SHAKE algorithm to constrain
bond lengths involving hydrogen atoms (55,56). Nonbonded interactions
were explicitly evaluated for distances below 9 A˚. The particle mesh Ewald
method was employed to treat long-range electrostatic interactions (57).
Constant pressure and temperature (NPT ensemble) were maintained by
weakly coupling the system to an external bath at 1 bar and 298 K, using
the Berendsen barostat and thermostat, respectively (58). To improve the
extraction of statistical data from the ensemble produced using the Berend-
sen thermostat we have used a relaxation time of 5 ps (59). Keeping in mind
that errors can be introduced by the usage of this thermostat, previous work
has shown that binding free energies (computed with MSM) in accordance
with experimental values can be estimated despite the thermostat being
used (60). Simulations were considered equilibrated after ~ 1 ns by inspec-
tion of convergence of total energy, temperature, and pressure. All
computed times presented in this study have as time 0 the beginning of
the production process. Total production times are 1200 ns for CPT,
1400 ns for CPT1, and 1100 ns for CPT2, and structures were saved every
20 ps. The Supporting Material provides further information as well as all
needed parameters (bonding, nonbonding (in Fig. S3 in the Supporting
Material), and charges) to reproduce the results presented in this paper.Binding free energies
The EMMA software package (61,62) was used to estimate binding free
energies using MSMs. This method is able to describe the dynamics of
complex systems through transitions between different states. The complete
simulation data for each compound (coordinates printed every 20 ps) were
initially aligned to a reference structure of the DNA backbone strand. The
MSM was built by following several steps (62) briefly described here: 1),
extract the Cartesian coordinates of the central platinum atom; 2), build
500 microstates using the k-means clustering (different number of cluster
were tested); 3), assign all trajectories frame into discrete microstates by
a Voronoi discretization; 4), certify the connectivity of these microstates
and determine the largest set of microstates; 5), ensure that the implied
timescale becomes constant after certain lag times (t), (see plateau in
Fig. S5, i.e., 100, 200, and 50 ns are chosen for estimating transition
matrices in CPT, CPT1, and CPT2, respectively). Once transition matrices
are defined, the stationary distribution of the microstate can be calculated
as p ¼ p T(t), which is the computing eigenvector of the transition
matrix with eigenvalue 1. Then, the potential mean force (PMF) profile,
Gi, was obtained by Boltzmann inversion of the stationary distribution,
MD simulations of cisplatin binding to DNA 423Gi ¼ kBTlogpi. After constructing the three-dimensional PMF, the bind-
ing free energy through DG0 ¼ kBTlogðvb=v0Þ  DW is computed. Here
kB is the Boltzmann constant, T ¼ 300 K, V0 ¼ 1661 A˚3 (for 1 M concen-
tration), Vb is the bound volume of the PMF, and DW is the difference from
the minimum (bounded state) and the bulk (unbounded state) PMF value.
Furthermore, the PCCAþ method has been used to determine the meta-
stable sets and validation of the MSM established by the Chapman-Kolmo-
gorov tests (see Fig. S6).RESULTS
Ligand-DNA dynamics
MD simulations using AMBER11 (45) software with CUDA
acceleration were performed for the species CPT, CPT1, and
CPT2 with more than 3,7 ms of accumulated simulation time,
with individual trajectories ranging from 80 to 200 ns. Table
S1 presents a summary of all simulations. Simulations were
initiated by positioning the ligand randomly an average 20 A˚
away from the DNA double helix. The DNA structure used
in the present work corresponds to an undamaged B-DNA
sequence (d(CCTCTGGTCTCC)$d(GGAGACCAGAGG))
from the PDB with entry 2K0V (53) identical to a
cisplatin-DNA complex where the ligand is complexed in a
GG (G6 and G7 in bold in the above representation and
shown in the left panel of Fig. 2) site in the major groove.
For simplicity purposes, we will refer to this G6G7 site as
the active site (AS), despite the fact that other less common
platination sites exist (14,19,63–65). The results from all
simulations are shown in Fig. 2.
In Fig. 2 we can see the initial position of the DNA mole-
cule along with all the relative positions occupied by the
central Pt atom through all simulations (only the initial
position of the DNA molecule is displayed but all frames
are aligned to this structure). For better visualization,
Fig. 3 shows the distance between the Pt atom and the N7
atom in G6, with a red horizontal line identifying visits to
the AS with distances inferior to 5 A˚. The data includesFIGURE 2 Relative position of the central platinum atom (yellow dots)
of CPT (left), CPT1 (center), and CPT2 (right) through the full extent
(1200 ns for CPT; 1400 ns for CPT1; 1100 ns for CPT2) of the simulations.
The nucleic bases are represented in different colors: pink—guanine (G);
green—cytosine (C); blue—adenine (A); gray—thymine (T). The two gua-
nines indicated in the left panel correspond to the most common lesion
region in the major groove. The identical positions can be seen also in
pink for the other two compounds. To see this figure in color, go online.all the individual trajectories with 1.2 ms for CPT, 1.4 ms
for CPT1, and 1.1 ms for CPT2.
We find that for CPT the AS was seldom visited by the
ligand that preferred to explore the full extent of the minor
groove (narrower region on the opposite side of the major
groove) where it is seen ‘‘jumping’’ from site to site (left
panel in Fig. 2). The ligand only visits the AS three times,
remaining there for very short periods of time, i.e., ~ 0.6%
of the total simulation time. Although a large amount of
points for CPT are >25 A˚ (away from DNA’s surface,
Fig. 3), CPT1 and CPT2 spend a large amount of time in
the surface of DNA and less time in the bulk of the solvent.
The pattern of binding sites, along the minor groove, for
the CPT1 molecule is similar to the parent drug. In addition
to these, the ligand now finds the AS much more frequently
than in the case of CPT. According to our simulations, the
ligand requires an average of 21 ns (for situations where
the ligand actually reaches the AS) to find the AS where it
remains 10% (with a slight preference for G7 (10%) vs.
G6 (8%)) of the total simulation time. The convergence of
the AS residence time percentage for CPT1 and CPT2 along
the entire simulation is shown in Fig. S1.
The di-aquo complex, CPT2, spends most of the time
close to the DNA double helices. It encounters the AS in
very short periods of time (in average less than 7 ns) where
it remains 39% of the total simulation time. In contrast to
CPT and CPT1, this compound locates the AS in all individ-
ual trajectories. We see that in the case of CPT2, there is a
clear preference for proximity to the G7 site where it is
seen 39% of the time in contrast to 24% observed for G6.
The sites in the minor groove, frequently visited by CPT
and CPT1 complexes, are rarely seen for this complex.
We have also examined the variations in Hbond patterns
along all the trajectories. Analyses show, as expected, very
different arrays for the three compounds (see Fig. S2).
CPT forms Hbonds essentially along the phosphate back-
bone and in the minor groove, with only 1% of Hbonds to
the major grove. In CPT1 both the major and minor grooves
form Hbonds. The most remarked difference, in agreement
with the populations, is seen for CPT2 where the main inter-
actions occur in the major groove.
In addition to the different binding sites observed for the
three compounds, the manner in which they approach the
AS diverges. In the case of the parent drug (in the few
instances that it reaches the AS), the compound approaches
the guanine site with the amine groups facing the N7 atoms
of guanines 6 and 7. This is clear from the left panel of
Fig. 4 (where the blue color corresponds to nitrogen atoms
in the amine ligands and green to Cl-). We have computed
the productive orientations1 and found that only 4.6% of all
frames found in the AS are in a suitable position for1Productive orientations are defined as 1) the total number of frames in which the Pt
atom is found less than 6 A˚ away is computed; then 2) the percentage of positions in
which one of the labile ligands heavy atoms (Cl for CPT and CPT1, OH2 for CPT1
and CPT2) is up to 4 A˚ distance from these guanines (N7).
Biophysical Journal 106(2) 421–429
FIGURE 3 Variation of the distance between the platinum atom and the N7 atom from G6 for the three complexes under study. Within each compound,
individual simulations are shown separately. To see this figure in color, go online.
424 Lucas et al.reaction. In all other cases the negatively charged chloro
ligands remain in the outer part, away from the N7 atoms,
in an unfavorable orientation for posterior ligand replace-
ment by guanine. In the case of the CPT1, in addition to
the amine groups, we observe the approximation of the
water ligand, in particular toward the G6 (Fig. 4, center;
the red corresponds to the oxygen atom from the water
ligands). We find 27% productive orientations for G6 and
22% for G7, the uneven orientation being consequence ofFIGURE 4 Relative position of the ligands: CPT (left), CPT1 (center),
and CPT2 (right) to the active site base guanines 6 and 7. The color scheme
is as follows: nitrogen (blue), chloride (green), and oxygen (red). To see this
figure in color, go online.
Biophysical Journal 106(2) 421–429CPT1 asymmetry. Finally, CPT2 has 27% productive orien-
tations equally distributed over the two guanines (Fig. 4,
right).
Although CPT is neutral, CPT1 and CPT2 have þ1
and þ2 formal charges, respectively. We have also found
that the two aquo complexes have a higher capability for
Hbond formation (given the extra water ligands). Knowing
these structural differences, we wanted to determine which
of these factors is the driving force for the different
behavior. For this, we artificially modeled a new compound,
CPTmodel, with hybrid characteristics. This complex has the
same structure as CPT but the partial charges in each atom
have been altered to emulate the point charges of CPT2 (þ2
net charge). The CPTmodel behaves as the di-aquo complex
with identical sites in the DNA surface being visited and
rapid introduction in the AS where it remains most of the
simulation. In fact, even the orientation in the AS is altered
with both the ‘‘pseudo’’ chloro ions (now positively charged
as a result of the summation of the water molecule’s partial
charges—charges available in the Supporting Material) and
the amine groups facing the guanines 6 and 7 alike the
behavior seen for CPT2.
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Computing binding free energies is not a simple task
because large amounts of data are necessary to attain statis-
tical convergence. In recent years, however, long molecular
dynamics simulations, through special purpose MD ma-
chines (such as Anton, Pittsburgh, PA (66)), running on
graphical processing units (GPU) (67) or grid computing
(68) are now possible. MSMs provide a systematic way to
decompose the data into meaningful substates and esti-
mating the transition probabilities between these states. In
this way it is possible, for example, to identify long-living
species, transition pathways, and reaction rates (62). Recent
studies have computed binding free energies for protein-
ligand interactions with excellent agreement with experi-
mental values (5,6). Thus, force fields together with accurate
parameterization of ligands appear to be reliable for a quan-
titative description of binding free energies as long as suffi-
cient sampling is provided. This opens the possibility for
obtaining binding energies in situations where experimental
measurements are challenging. In this study, we estimated
the DNA-ligand binding free energies for the electrostatic
preassociation process and present a kinetic model for the
process. Using MSMs, we produced potential mean force
(PMF) surfaces for each compound following the procedure
explained in the Methods section (two-dimensional PMF
contour plots of Fig. S4). Then we have measured the total
binding energy for the ligand bound in any region of the
DNA molecule (considering all possible binding sites) and
the local binding energy in the AS. All energies are summa-
rized in Table 1.
The overall binding free energy for cisplatin’s preasso-
ciation in the complete DNA’s surface is –1.45 (standard
deviation 5 0.10) kcal/mol. This low value reflects the
weak affinity this ligand has for DNA. The binding free en-
ergy has been computed to be –2.08 (5 0.17) kcal/mol for
CPT1, and –2.77 (5 0.10) kcal/mol for CPT2. As discussed
earlier, CPTfinds theAS invery few occasions, and it was not
possible to compute the binding free energy for it, which we
considered negligible.CPT1on the other hand is seenvisiting
theAS quite often, which translates in a local binding free en-
ergy of –0.78 (5 0.19) kcal/mol. In the case of CPT2 where
the main binding site is located in the AS the binding free en-
ergy is –1.19 (5 0.23) kcal/mol. Compared with most inter-
calators, these are quite weak affinities. Recent MD studies
with daunomycin, a common anticancer drug, show a bind-TABLE 1 Binding free energies calculated with MSM and
MM-PBSA
Binding free energy CPT CPT1 CPT2
MSM active site – –0.8 –1.2
MSM global –1.4 –2.1 –2.8
MM-PBSA global –2.4 –3.3 –3.8
SMD –1.6 –2.6 –2.8
All values in this table are in kcal/mol.ing free energy of about –10 kcal/mol (1). However, this
drug exerts its action solely by stacking with DNAwhereas
the platinum-based drugs irreversibly bind to DNA.
We have also used the more traditional MM-PBSA
method to compute the total binding energy (method’s de-
tails can be found in the Supporting Material) (69). The cal-
culations summarized in Table 1 retrieved –2.4 kcal/mol for
CPT, –3.3 kcal/mol for CPT1, and –3.8 kcal/mol for CPT2.
MM-PSBA is known for overestimating binding free en-
ergies partially because of incorrect entropic contributions
(70). Having this in mind, despite the ~ 1 kcal/mol bias in
the MM-PBSA results, the relative interactions are in
good agreement between the two methods. Again CPT pre-
sents a lower binding affinity than its aquation products.
Steered molecular dynamics with the Jarzynski estimator
(71) were also performed to compute the binding free en-
ergies for the three compounds. More than 450 independent
simulations were performed to adequately estimate these
energies. For more details on the method please consult
the Supporting Material. The results show, in agreement
with the other two methods, a lower binding affinity for
CPT (–1.6 kcal/mol) whereas CPT1 and CPT2 show –2.6
and –2.8 kcal/mol, respectively. These results encourage
us to believe that the MSM binding energies are a good
approximation to the absolute values.Kinetics and cisplatin binding mechanism
MSMs are a useful tool for extracting kinetic information
from atomistic simulations. For this, we have identified
the most populated states for each simulation and how these
were connected. In Fig. 5 we show the most populated states
for each compound. In the case of CPT, six metastable statesFIGURE 5 Network of the most relevant transition pathways for the asso-
ciation and dissociation processes and binding sites. The clusters represented
by the different colors and letters correspond to independent occupation
sites. The yellow beads match the clusters coinciding with the bulk solution
(S state). The orange spheres in CPT1 and CPT2match the expected binding
site in the major groove. A putative kinetic mechanism for ligand binding
for each of the three figures is depicted (lower panel). The size of the arrows
indicates the relative reaction rate (by orders of magnitude) for each individ-
ual process. To see this figure in color, go online.
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426 Lucas et al.were identified: A (green), B (blue), C (purple), D (red), E
(mauve), and the bulk solvent (S) in yellow. In the lower
part of the left panel we see the relative rate constants for
each process with solvent exchange rate constants corre-
sponding to the arrows pointing in and out of each state.
The size of the arrows correlates with the relative rate con-
stants (values are available in Table S2). Fig. 5 illustrates
that the fastest processes in CPT correspond to exit from
states A, B, D, and E so it would seem that the dissociation
rate is larger than the association. This is in agreement with
the low affinity observed for CPT. The location of these sites
are as follows. The A state is located in one extremity of the
DNA double helix close to the N3 atoms of A22 and G23.
The B state is close to A20 and G21. The C state is ‘‘behind’’
the major groove GG site close to the two guanine N3
atoms. The D state is close to A17 and C18. Finally, the E
state is in DNA’s 50 terminal of the second strand close to
A15 and G16. It is interesting to observe that in the minor
groove for both CPT and CPT1 there is a clear preference
for binding in the AG sequences.
In the case of CPT1, we find the minor groove states
already seen in CPT and two additional states: F and G.
The F (pink) state in Fig 5 is seen in the entrance of the
major groove and is connected to the G (orange) state
(in the major groove) and the D state (in the minor groove).
The G state, located in the AS, is only connected to the sol-
vent and to the F state. The largest rate constant for this sys-
tem is the binding from the solvent in the G (AS) state and
exit from the F state. For CPT2, we had already seen that the
ligand binds very quickly to the AS and does not visit the
minor groove often. By observation of the right panel of
Fig. 5 we can confirm that the binding process for CPT2
is different from the other two compounds. The states in
the minor groove seen in the other two complexes are not
found here. The binding process flows both from the bulk
directly to the AS (G state) or passing by both site E and
F to the G state.Specific DNA analyses
The conformational modifications that occur on the DNA
molecule upon the formation of Pt-DNA adducts have
been extensively studied through x-ray and NMR structures
as well as computational work (54,64,72). The large flexi-
bility of the DNAmolecules allows it to accommodate intra-
strand cross-links by adopting a bent structure. In this study
we were interested in observing whether the noncovalent
binding of the ligands studied would have any effect on
DNA’s structure. For this, we employed the Curvesþ soft-
ware (73). We analyzed the axis bending of the three
systems along the complete simulation time. The results
show that for all three compounds significant axis bending
occurs that is not necessarily associated to the binding
process. We do not observe any particular trend and assent
that covalent binding is required for significant bendingBiophysical Journal 106(2) 421–429(in the direction of the major groove) of the molecule’s
backbone. In Fig. S7 we compare the results for the two
cases: CPT and CPT2.
The presence of a spine of hydration in B-DNA, which is
essential to maintain its native conformation, is well known
(74,75). Visual inspection of the spine of hydration along
the simulations confirms several permanent hydration shells
in the minor groove, which are disrupted with the introduc-
tion of ligands in this region. The movie S1 simulates one
such event.DISCUSSION
It has been theorized that cisplatin’s cytotoxicity is attribut-
able to its ability to bind, cross-link, and structurally distort
DNA. When DNA is cross-linked, complex repair mecha-
nisms are activated ultimately leading to cell death. Despite
the limitations of cisplatin-based therapy (i.e., its side
effects and its intrinsic and acquired resistance), its amazing
cure rates for some malignancies, in particular in testicular
cancer, make it a promising model in oncology research.
Strategies today include modified versions of cisplatin
with improved single and multinuclear platinum complexes,
Pt(IV) prodrugs as well as specific delivery through, for
example, nanoparticules (43,76–78). Current and future
developments could benefit from a complete understanding
of the dynamical interactions of these compounds especially
on how they locate their cytotoxic targets. In this work,
we sought to elucidate the preassociation mechanism of
cisplatin and its hydrolysis products to DNA. Furthermore,
we sought to show that routine calculations are capable in
such a study.
The results previously described indicate that the replace-
ment of the chloro ions by the aquo ligands has a drastic
effect on the way the drug approaches DNA. The binding
sites differ considerably and also the orientation in which
the compounds approach the nucleic bases is divergent.
The replacement of the first chloro ligand by a water mole-
cule not only increases the amount of time the ligand spends
in the AS (from 0.6% to 10%) but also the number of pro-
ductive orientations (4.6% to 27%). Of these productive ori-
entations in CPT1, 27% are closer to the G6 whereas 22%
are closer to the G7. The fact that the water ligand is, on
average, closer to the G6 site could favor this nucleic base
as preferential site for the first nucleophilic substitution. In
fact, the preference for first platination in the 50 position is
well known (36,79,80). In the case of the second chloro
replacement, the increase in time spent in the AS is even
more significant. CPT2 spends 39% of the simulation time
with 27% productive orientations equally distributed be-
tween the two guanines. Another interesting aspect from
this study is the type of potential adducts that can be formed
according to the positions observed along the DNA strands.
The main adduct for CPT1 and CPT2 are found in the AS
(G state in Fig. 5). In addition, other potential binding sites
MD simulations of cisplatin binding to DNA 427have been observed, especially in AG sequences (close to
adenine and guanine N3 atoms) in the minor groove. These
results confirm that diverse platination sites can be expected.
Experimentally the main adducts are seen in 1,2-intrastrand
cross-link between the N7 atoms of two adjacent purine ba-
ses GG (60% to 65%) or AG (20% to 25%) (14,19,63–65).
Further studies with the CPTmodel compound (identical to
CPT but with a total charge of þ2) show that it quickly
moves into the AS like the di-aquo complex. It is interesting
to see that even though this compound is unable to form the
Hbond network of CPT2 it behaves in an identical manner
showing that the fast diffusion of the ligand to the major
groove is mainly driven by electrostatics. Recent molecular
dynamics studies by Gue´roult et al. (81), which investigated
the interaction between Mg2þ and DNA, showed that diva-
lent cations preferentially bind in DNA’s major groove. The
authors proposed that the electrostatic potential in the major
groove is particularly attractive for cations. The results
found in the present study confirm the strong electrostatic
nature of the preassociation process for the positively
charged compounds. Furthermore, our results indicate no
meaningful distortion of the DNA structure (bending and
unwinding of the double helix) (54,64,72,82), associated
with this electrostatic preassociation.
Microsecond time-scale simulations appear to be suffi-
cient to describe the cisplatin-DNA binding process and to
derive free energies through the transition probabilities in
the MSMs. Indeed one of the main advantages of the use
of MSM consists in determining just how much data is
needed to compute the binding free energies (and avoid ex-
tending simulations beyond what is necessary). The results
indicate lower global interaction (–1.4 kcal/mol) between
the CPT compound and DNA but slightly more favorable
for the aquo complexes (–2.1 and –2.8 kcal/mol for
CPT1 and CPT2, respectively). Most importantly, whereas
for CPT the binding free energy in the AS is negligible,
CPT1 and CPT2 show a local binding free energy of –0.8
and –1.2 kcal/mol, respectively evidencing their higher affin-
ity to bind in this site. Since cisplatin binds covalently to
DNA, no experimental information exists on the electro-
static preassociation. As mentioned, recent developments
in computationalmodeling sampling and analysis techniques
can fill this gap. We have used different theoretical methods
ranging from inexpensive MM-PBSA to unbiased molecular
dynamics simulations associated with MSM. We see that,
despite small differences between the methods, all indicate
that the parent drug is the one exhibiting the lower affinity
toward DNA whereas the charged aquo products interact
with DNA more strongly.
For many years, new platinum-based drugs have been
proposed based on structural assumptions. Most of the
new compounds put forward followed basic rules, such as
cis disposition of the two amines, a minimum of one N-H
group on the amine, leaving groups with weaker trans effect
than the amine, etc. However, it has become clear that moreinformation is needed to effectively improve the clinical
value of this family of compounds. For this, it is essential
to understand all steps involved. With the improvement of
computational techniques, details have been revealed at
the molecular level. We now know that differences exist
in the hydrolysis rate of cisplatin, carboplatin, oxaliplatin,
and nedaplatin. Variations in the first and second hydrolysis
rates have been suggested to be responsible for differences
in activity (32). Several authors have also been interested
in how these drugs covalently bind to guanine and adenine
bases using small models and DFT methods. However, it
is important to know exactly how these drugs approach
the binding sites in DNA and for this reason a complete un-
derstanding of the preassociation process is fundamental.
Not only the studies presented here can establish differences
in the affinity of different drugs to DNA but most impor-
tantly this type of work will allow for an adequate
description of the covalent binding by knowing the correct
orientation of the drug in the binding site before reaction.
Overall, we show that the simplicity of the system when
compared with protein-ligand interactions permit gathering
sufficient data to map all-atom association/dissociation
mechanisms in DNA-ligand interactions. The computa-
tional cost, both in CPU time and hardware, is quite modest:
1 wk for ligand parameterization (if needed), some weeks
for running the MD simulations, and ~ $5,000 in hardware
units. This in turn, allows for the extraction of thermody-
namic and kinetic information, which are of high value.
This study sets the precedent for unbiased DNA-ligand sim-
ulations of more complex molecules such as intercalators,
and its extension to diverse DNA sequences.SUPPORTING MATERIAL
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